Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million

MT Newswires Live

Feb 11, 2025

Grace Therapeutics (GRCE) rose nearly 8% in recent Monday trading after it said it entered into securities purchase agreements for a private placement financing of up to $30 million with healthcare-focused institutional investors.

The financing consists of an initial upfront funding of about $15 million, with an additional potential $15 million if accompanying warrants are exercised for cash. The deal is expected to close on Tuesday, subject to customary closing conditions.

As part of the financing, Grace Therapeutics will issue about 4.4 million common shares, or pre-funded warrants in lieu thereof, along with warrants to purchase up to an additional 4.4 million shares at a combined purchase price of $3.395 per share.

Each warrant allows the holder to purchase one share at $3.395 and will expire either 60 days after the US Food and Drug Administration approves the New Drug Application for GTx-104 or on Sept. 25, 2028.

If all warrants are exercised, Grace Therapeutics could receive up to $15 million in additional proceeds.

The company, formerly Acasti Pharma, plans to use the funds to support general operations and the pre-commercial development of GTx-104.

Price: 3.53, Change: +0.26, Percent Change: +7.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510497896"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510497896\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510497896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 02:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510497896","market":"hk","top_or_hot":-1,"title":"Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million","media":"MT Newswires Live","content":"<html><body><p> Grace <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (GRCE) rose nearly 8% in recent Monday trading after it said it entered into securities purchase agreements for a private placement financing of up to $30 million with healthcare-focused institutional investors.</p><p>The financing consists of an initial upfront funding of about $15 million, with an additional potential $15 million if accompanying warrants are exercised for cash. The deal is expected to close on Tuesday, subject to customary closing conditions.</p><p>As part of the financing, Grace Therapeutics will issue about 4.4 million common shares, or pre-funded warrants in lieu thereof, along with warrants to purchase up to an additional 4.4 million shares at a combined purchase price of $3.395 per share.</p><p>Each warrant allows the holder to purchase one share at $3.395 and will expire either 60 days after the US Food and Drug Administration approves the New Drug Application for GTx-104 or on Sept. 25, 2028.</p><p>If all warrants are exercised, Grace Therapeutics could receive up to $15 million in additional proceeds.</p><p>The company, formerly Acasti Pharma, plans to use the funds to support general operations and the pre-commercial development of GTx-104.</p><p>Price: 3.53, Change: +0.26, Percent Change: +7.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-11 02:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Grace <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (GRCE) rose nearly 8% in recent Monday trading after it said it entered into securities purchase agreements for a private placement financing of up to $30 million with healthcare-focused institutional investors.</p><p>The financing consists of an initial upfront funding of about $15 million, with an additional potential $15 million if accompanying warrants are exercised for cash. The deal is expected to close on Tuesday, subject to customary closing conditions.</p><p>As part of the financing, Grace Therapeutics will issue about 4.4 million common shares, or pre-funded warrants in lieu thereof, along with warrants to purchase up to an additional 4.4 million shares at a combined purchase price of $3.395 per share.</p><p>Each warrant allows the holder to purchase one share at $3.395 and will expire either 60 days after the US Food and Drug Administration approves the New Drug Application for GTx-104 or on Sept. 25, 2028.</p><p>If all warrants are exercised, Grace Therapeutics could receive up to $15 million in additional proceeds.</p><p>The company, formerly Acasti Pharma, plans to use the funds to support general operations and the pre-commercial development of GTx-104.</p><p>Price: 3.53, Change: +0.26, Percent Change: +7.95</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510497896","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510497896","pubTimestamp":1739213048,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Grace Therapeutics  rose nearly 8% in recent Monday trading after it said it entered into securities purchase agreements for a private placement financing of up to $30 million with healthcare-focused institutional investors.The financing consists of an initial upfront funding of about $15 million, with an additional potential $15 million if accompanying warrants are exercised for cash. The deal is expected to close on Tuesday, subject to customary closing conditions.As part of the financing, Grace Therapeutics will issue about 4.4 million common shares, or pre-funded warrants in lieu thereof, along with warrants to purchase up to an additional 4.4 million shares at a combined purchase price of $3.395 per share.Each warrant allows the holder to purchase one share at $3.395 and will expire either 60 days after the US Food and Drug Administration approves the New Drug Application for GTx-104 or on Sept. 25, 2028.If all warrants are exercised, Grace Therapeutics could receive up to $15 mil","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LENZ":"Therapeutics","GRCE":"GRACE THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Grace Therapeutics在私募融资高达3000万美元后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRCE":0.9,"LENZ":1},"content_text":"Grace Therapeutics (GRCE) rose nearly 8% in recent Monday trading after it said it entered into securities purchase agreements for a private placement financing of up to $30 million with healthcare-focused institutional investors.The financing consists of an initial upfront funding of about $15 million, with an additional potential $15 million if accompanying warrants are exercised for cash. The deal is expected to close on Tuesday, subject to customary closing conditions.As part of the financing, Grace Therapeutics will issue about 4.4 million common shares, or pre-funded warrants in lieu thereof, along with warrants to purchase up to an additional 4.4 million shares at a combined purchase price of $3.395 per share.Each warrant allows the holder to purchase one share at $3.395 and will expire either 60 days after the US Food and Drug Administration approves the New Drug Application for GTx-104 or on Sept. 25, 2028.If all warrants are exercised, Grace Therapeutics could receive up to $15 million in additional proceeds.The company, formerly Acasti Pharma, plans to use the funds to support general operations and the pre-commercial development of GTx-104.Price: 3.53, Change: +0.26, Percent Change: +7.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}